🎊Schaeffer’s 2026 Stock Picks are LIVE

Our 2025 picks had a combined gain of more than 1,000%!  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

December 31, 2025 Hi – and Happy New Year's Eve!  Before the year wraps up, I always like to slow things down for a moment and look back at the year that just passed. Not just how the market did, but how things went personally and financially as well.  So let me ask you something:  How did 2025 treat you as an investor? Did you make progress toward the goals you set out for yourself, or do you feel like there are areas where you want to be more prepared going forward?  That question is always what drives our work at this time of year.  Every year at Schaeffer's, we put together a short list of what we believe are our best trade ideas for the year ahead.  It's a process built around careful research, technical analysis, and sentiment work, with the goal of identifying opportunities we want to be positioned in before the year really gets going.  So, without further ado…  Presenting Schaeffer's Top Stock Picks for 2026 Report!  Each name in this report was selected because price action, positioning, and longer-term trends were beginning to align, often before those stories became widely recognized. The objective is not to predict every short-term move, but to identify setups where the risk-reward looks favorable heading into the year ahead.  Before looking forward, it's worth briefly looking back.  Our 2025 Stock Picks delivered a combined gain of more than 1,000%! That performance came from a collection of ideas working together, with massive wins on names like Bloom Energy, Deutsche Bank, Nebius Group, and more.  But what mattered more than the flashy numbers was the consistency across the list and the discipline behind how each idea was selected and held.  That consistency came from identifying opportunities early and allowing the underlying trends to develop, rather than reacting to short-term noise as it appeared… and that's the exact plan we have for our 2026 picks as well.  Inside Schaeffer's Top Stock Picks for 2026, you'll find:  A curated list of my top stock ideas for the year ahead Detailed technical charts for each pick The reasoning behind why each name made the list A framework you can reference throughout 2026  This level of research is typically reserved for our premium services and reflects a process that normally carries a value of $3,995.  For this year-end release, I wanted to make it easy for more investors to start 2026 on solid footing.  That's why Schaeffer's Top Stock Picks for 2026 is available today for $20!  Think of this report as a roadmap you can carry with you throughout the year. Whether you're building positions gradually or simply want a clearer sense of where the strongest opportunities may be developing, it's designed to give you direction before the year really gets underway.  If you want to begin 2026 with clarity, confidence, and a plan you can actually reference, this is where I would start.  Click below to access the report now.  Get the 2026 Stock Picks Sincerely, Bernie Schaeffer  Founder & CEO  Schaeffer's Investment Research 📧 service@sir-inc.com 🌐 http://www.schaeffersresearch.com 📞1-800-448-2080  International 1-513-589-3800   Update your email preferences or unsubscribe here © 2025 Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 450 Cincinnati, Ohio 45242, United States of America Terms of Service

(NYSE American: MAIA) Is A Low Float Profile Backed By 2 Explosive Analyst Targets

A forward-looking biotech company is quietly

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: MAIA) Is A Low Float Profile Backed By 2 Explosive Analyst Targets *Click Here To Get Our Alerts Faster Via SMS* December 31st Dear Reader, A forward-looking biotech company is quietly reshaping how we think about next-generation therapeutics. By merging cutting-edge science with a disciplined development framework, they’re tackling complex illnesses with a focus on precision and patient outcomes. The team combines deep domain expertise with agile operations, enabling rapid translation from concept to candidate. Their work sits at the intersection of biology, technology, and data, aiming to unlock new pathways and expand what’s possible in medicine. If you’re curious about breakthrough science and the behind-the-scenes effort that turns ideas into potential treatments, this group warrants a closer look. Plus, back in 2024, when I brought this profile to your attention, it exploded approx. 275% within months. And with a low float, two strong analyst targets pointing to triple-digit potential upside, and a major milestone notched in a Phase 3 pivotal trial, this little-known NYSE American profile is topping our watchlist Wednesday: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. #4. A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. #5. Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. Earlier this month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Tuesday's closing valuation, that provides MAIA with upside potential over 950%! Check out some key report highlights: Conclusion. The start of Phase 3 is an important milestone toward FDA approval. If the study replicates the recent data from the Phase 2 trial, ateganosine could become significant new therapy for third-line NSCLC. We believe this would also provide significant proof-of-concept to support earlier use. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. According to info from the Yahoo Finance website, MAIA has a relatively low float. The website reports this profile to have roughly 31.98Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If more positive company news pops up towards the end of 2025, could it provide a breakout spark when paired with this volatility potential? ----- #3. MAIA Potential Catalyst - Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. Last month, an analyst at Diamond Equity Research provided an update note on their (NYSE: MAIA) coverage. In the update, they retagged MAIA with a target of $10.27. From Tuesday's close, that target provides MAIA with a potential upside of over 650%. Here's some highlights from the report: Valuation: ... With continued positive readouts, the initiation of THIO-104 (Phase 3 study) remains a key potential valuation catalyst, marking progression towards controlled clinical validation and potential registration. We have revised our valuation model to reflect the recent Q3 financial results, updated share count, and reassessed comparable company analysis, reiterating our valuation of $10.27 per share contingent on successful execution by the company. ----- #4. MAIA Potential Catalyst - A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient has been dosed in the Company’s THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). The multicenter, open-label trial of patients who are resistant to CPI and chemotherapy treatments, is designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 patients. MAIA has received regulatory approval to screen patients in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia. Screening and enrollment are now underway. “Our strategy to bring our telomere-targeting treatment to market is proceeding according to plan as we advance our ateganosine program to a Phase 3 trial. This larger trial will provide us a robust dataset to support our case for commercial approval by the U.S. FDA,” said Vlad Vitoc, M.D., CEO of MAIA. “We have many sites in several countries already screening patients, and with our first patient dosed, we have achieved a key milestone along our path to potential FDA commercial approval. We expect to see Phase 3 results consistent with Phase 2 trial data showing median survival of 17.8 months compared to approximately six months of survival from chemotherapy. We are confident that ateganosine could become the new treatment standard for patients suffering from this devastating disease.” ... Read the full article here. ----- #5. MAIA Potential Catalyst - Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. MAIA Biotechnology Announces Open Market Purchases by CEO and Directors CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common st-ock at market price between November 21 and 28, 2025. The average common stock price was $1.06. Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares in the open market at an average price of $1.04 per share. “Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date, we believe in ateganosine’s potential to improve the lives of patients diagnosed with non-small cell lung cancer and become a new standard of care.” ... Read the full article here. ----- MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. #4. A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. #5. Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. ----- We're kicking-off coverage on MAIA Biotechnology, Inc. (NYSE American: MAIA). As soon as updates are available, we'll get them out to you quickly. Stay tuned. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/31/2025 and ending on 12/31/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred fifty three thousand seven hundred fifty USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/maia-wvkom/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice

Low Float (NYSE American: MAIA) Takes Control Of Wednesday's Watchlist (2 Weighty Analyst Targets)

A forward-looking biotech company is quietly reshaping how we think about next-generation therapeutics.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Low Float (NYSE American: MAIA) Takes Control Of Wednesday's Watchlist (2 Weighty Analyst Targets) *Click Here To Get Our Alerts Faster Via SMS* December 31st Greetings Readers, A forward-looking biotech company is quietly reshaping how we think about next-generation therapeutics. By merging cutting-edge science with a disciplined development framework, they’re tackling complex illnesses with a focus on precision and patient outcomes. The team combines deep domain expertise with agile operations, enabling rapid translation from concept to candidate. Their work sits at the intersection of biology, technology, and data, aiming to unlock new pathways and expand what’s possible in medicine. If you’re curious about breakthrough science and the behind-the-scenes effort that turns ideas into potential treatments, this group warrants a closer look. Plus, back in 2024, when I brought this profile to your attention, it exploded approx. 275% within months. And with a low float, two strong analyst targets pointing to triple-digit potential upside, and a major milestone notched in a Phase 3 pivotal trial, this little-known NYSE American profile is topping our watchlist Wednesday: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. #4. A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. #5. Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. Earlier this month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Tuesday's closing valuation, that provides MAIA with upside potential over 950%! Check out some key report highlights: Conclusion. The start of Phase 3 is an important milestone toward FDA approval. If the study replicates the recent data from the Phase 2 trial, ateganosine could become significant new therapy for third-line NSCLC. We believe this would also provide significant proof-of-concept to support earlier use. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. According to info from the Yahoo Finance website, MAIA has a relatively low float. The website reports this profile to have roughly 31.98Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If more positive company news pops up towards the beginning of 2026, could it provide a breakout spark when paired with this volatility potential? ----- #3. MAIA Potential Catalyst - Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. Last month, an analyst at Diamond Equity Research provided an update note on their (NYSE: MAIA) coverage. In the update, they retagged MAIA with a target of $10.27. From Tuesday's close, that target provides MAIA with a potential upside of over 650%. Here's some highlights from the report: Valuation: ... With continued positive readouts, the initiation of THIO-104 (Phase 3 study) remains a key potential valuation catalyst, marking progression towards controlled clinical validation and potential registration. We have revised our valuation model to reflect the recent Q3 financial results, updated share count, and reassessed comparable company analysis, reiterating our valuation of $10.27 per share contingent on successful execution by the company. ----- #4. MAIA Potential Catalyst - A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient has been dosed in the Company’s THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). The multicenter, open-label trial of patients who are resistant to CPI and chemotherapy treatments, is designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 patients. MAIA has received regulatory approval to screen patients in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia. Screening and enrollment are now underway. “Our strategy to bring our telomere-targeting treatment to market is proceeding according to plan as we advance our ateganosine program to a Phase 3 trial. This larger trial will provide us a robust dataset to support our case for commercial approval by the U.S. FDA,” said Vlad Vitoc, M.D., CEO of MAIA. “We have many sites in several countries already screening patients, and with our first patient dosed, we have achieved a key milestone along our path to potential FDA commercial approval. We expect to see Phase 3 results consistent with Phase 2 trial data showing median survival of 17.8 months compared to approximately six months of survival from chemotherapy. We are confident that ateganosine could become the new treatment standard for patients suffering from this devastating disease.” ... Read the full article here. ----- #5. MAIA Potential Catalyst - Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. MAIA Biotechnology Announces Open Market Purchases by CEO and Directors CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common st-ock at market price between November 21 and 28, 2025. The average common stock price was $1.06. Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares in the open market at an average price of $1.04 per share. “Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date, we believe in ateganosine’s potential to improve the lives of patients diagnosed with non-small cell lung cancer and become a new standard of care.” ... Read the full article here. ----- MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 950% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Potential Could Be Significantly Heightened Based On MAIA's Low Float. #3. Another Analyst Target Suggests Over 650% Potential Upside From Tuesday's Close. #4. A Major Milestone Is Achieved With First Patient Dosing In THIO-104 Phase 3 Trial. #5. Insider Purchases Could Strike A Chord Of Significant Confidence In The Company's Future. ----- We're kicking-off coverage on MAIA Biotechnology, Inc. (NYSE American: MAIA). As soon as updates are available, we'll get them out to you quickly. Stay tuned. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/31/2025 and ending on 12/31/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred fifty three thousand seven hundred fifty USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/maia-wvkom/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice